Ratings AstraZeneca PLC Xetra

Equities

ZEG

GB0009895292

Market Closed - Xetra Other stock markets 16:35:31 07/06/2024 BST			5-day change	1st Jan Change
148.2 ^EUR	0.00%		+3.42%	+21.42%

06-07	ASTRAZENECA : JP Morgan reiterates its Buy rating	ZD
06-05	Department of Health - Abu Dhabi and AstraZeneca Expand Partnership During Bio International Convention 2024 to Establish New Rare Diseases Centre of Excellence	CI

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Sales forecast by analysts have been recently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The firm trades with high earnings multiples: 22.16 times its 2024 earnings per share.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
Over the past twelve months, analysts' opinions have been revised negatively.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ASTRAZENECA PLC	+21.42%	250B	-
ELI LILLY AND COMPANY	+45.82%	754B	C+
NOVO NORDISK A/S	+40.95%	630B	B
JOHNSON & JOHNSON	-6.16%	352B	C+
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	298B	C+
NOVARTIS AG	+11.88%	217B	B-
ROCHE HOLDING AG	-0.78%	216B	A+
AMGEN INC.	+5.90%	164B	C+
PFIZER, INC.	-0.73%	163B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes